Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002508 | Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 1 / Phase 2 | — | Temple UniversityOTHER | 1 | Oct 1, 2010 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 |
| clinicaltrials |
| NCT00217555 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217568 | Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00109993 | Campath-1H + FK506 and Methylprednisolone for GVHD | completed | Phase 2 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 11, 2010 | clinicaltrials |
| NCT00410657 | Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2010 | clinicaltrials |
| NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00004157 | Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00010283 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00261027 | Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer | completed | Phase 2 | 30 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00291837 | CT-2106 for the Second Line Treatment of Ovarian Cancer | completed | Phase 2 | 40 | CTI BioPharmaINDUSTRY | 3 | Feb 26, 2010 | clinicaltrials |
| NCT00239980 | Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) | completed | Phase 2 | 77 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Feb 3, 2010 | clinicaltrials |
| NCT00461786 | A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 4, 2009 | clinicaltrials |
| NCT00034151 | Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | completed | Phase 2 | 52 | Achieve Life SciencesINDUSTRY | 0 | Jun 4, 2009 | clinicaltrials |
| NCT00191334 | Gemcitabine in Ovarian Cancer | completed | Phase 2 | 50 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 27, 2009 | clinicaltrials |
| NCT00113789 | Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer | completed | Phase 2 | 21 | AmgenINDUSTRY | 0 | Feb 13, 2009 | clinicaltrials |
| NCT00400348 | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer | completed | Phase 2 | 18 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Nov 25, 2008 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
| NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 7 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
| NCT00070967 | Acupuncture to Improve Quality of Life in Patients With Advanced Cancer | completed | Phase 2 | 40 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00231075 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | completed | Phase 2 | 75 | ARCAGY/ GINECO GROUPOTHER | 1 | Nov 3, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Oct 1, 2010source: clinicaltrials